|
Patent landscape, scope, and claims: |
The Scope, Claims, and Patent Landscape of U.S. Patent 9,662,398
Summary
U.S. Patent No. 9,662,398, granted on May 30, 2017, to Amgen Inc., pertains broadly to a novel class of monoclonal antibodies targeting specific variations of the protein interleukin-23 (IL-23), crucial in inflammatory and autoimmune diseases. This patent signifies a strategic claim in biologics, specifically in the therapeutic modulation of IL-23 pathways. Its scope encompasses a set of antibody sequences, methods of use, and manufacturing processes directed at treating conditions such as psoriasis, Crohn’s disease, and other IL-23 related disorders. The patent landscape surrounding this patent is characterized by intense competition among biologics companies, both in novel antibody inventions and method claims, with primary relevance in the autoimmune biologics market.
What Is the Scope of U.S. Patent 9,662,398?
1. Patent Classification and Core Technical Focus
2. Antibody Sequence and Structural Claims
- Claimed Antibody Sequences:
The patent explicitly claims certain amino acid sequences (e.g., Complementarity Determining Regions [CDRs]) within the variable regions of the heavy and light chains. For example:
| Claimed Sequence ID |
Description materialized from the sequence** |
| SEQ ID NO: 1 |
Heavy chain V-region sequence |
| SEQ ID NO: 2 |
Light chain V-region sequence |
-
Claim Scope of Antibody Variants:
The claims include not only the explicitly disclosed sequences but also conservative modifications, variants, and antibody constructs with similar binding characteristics, providing broad patent protection.
-
Binding Specificity:
Claims specify high-affinity binding to human IL-23 p19 with an affinity (Kd) typically less than 1 nanomolar, which is critical for therapeutic efficacy.
3. Method of Use and Manufacturing Claims
-
Therapeutic Methods:
Claiming administration of the antibody for treating IL-23 mediated conditions such as:
- Psoriasis
- Crohn’s disease
- Ulcerative colitis
- Other autoimmune indications
-
Manufacturing Processes:
Claims extend to recombinant production techniques, including stable cell lines, purification methods, and formulation specifics.
4. Patent Claims:
| Type of Claim |
Scope |
Details |
| Composition of Matter |
Broad |
Monoclonal antibody sequences, variants, derivatives |
| Method of Use |
Medium |
Treatment of autoimmune diseases using the claimed antibodies |
| Manufacturing Claims |
Narrow |
Cell lines, purification, formulation methods |
Note: These claims collectively provide a comprehensive legal shield, covering both the molecules themselves and their applications.
Patent Landscape Analysis
1. Competitive Patents and Counterparts
-
Key Patents in IL-23 mAbs:
The patent landscape includes milestones such as U.S. Patent 8,567,434 (Amgen), which broadly covers anti-IL-23 antibodies, and newer filings that claim optimized or different epitope-specific antibodies.
-
Major Competitors:
- Janssen (guselkumab)
- AbbVie (risankizumab)
- Novartis (tildrakizumab)
These biologics target IL-23 and have overlapping claims or distinct but related antibody sequences, creating a complex landscape of patent fences and freedom-to-operate considerations.
2. Patent Family and Priority
-
Priority Date:
The earliest priority filing was in 2014, indicating a strategic positioning during the growing IL-23 antibody field.
-
Patent Families:
U.S. patent 9,662,398 is part of a broader patent family that includes related applications in Europe, Japan, and China, securing global coverage.
Comparison with Related Patents
| Patent/Publication |
Owner/Assignee |
Focus |
Key Claims |
| US 8,567,434 |
Amgen |
Broad anti-IL-23 antibodies |
Composition and methods |
| US 9,410,578 |
Janssen |
Guselkumab-related claim |
Antibody specific to p19 |
| WO 2016/036872 |
Novartis |
Tildrakizumab specifics |
Antibody structure and use |
Note: U.S. 9,662,398 offers a narrower but highly specific set of claims, potentially overlapping with these patents, especially regarding particular sequences.
Critical Analysis of Claims and Scope
Strengths:
- Sequence-specific claims render strong intellectual property protection for the antibody molecules.
- Broad method claims extend protection to generic uses, assuming antibody sequences are non-anticipated by prior art.
- Inclusion of variants enhances patent durability against design-around efforts.
Limitations:
- Claims relying heavily on specific sequences may be challenged if identical sequences are found in prior art.
- Therapeutic claims are vulnerable if similar method claims are disclosed elsewhere, especially for common autoimmune indications.
Implications for Patent Holders and Industry
- The patent reinforces Amgen’s position in IL-23 biologics, potentially blocking development of similar therapeutic antibodies with comparable sequences.
- The scope suggests the patent could serve as a basis for licensing negotiations or litigation, especially given the lucrative autoimmune biologic market projected to reach USD 22 billion by 2027 (per Allied Market Research).
Conclusion: The Landscape in a Nutshell
| Aspect |
Details |
| Scope |
Monoclonal antibodies targeting IL-23 p19 with specific sequences; methods of therapeutic use and manufacturing |
| Claims |
Sequence-specific, antibody variants, treatment methods, manufacturing protocols |
| Landscape |
Competitive with key patents from Janssen, AbbVie, and Novartis; part of a dense patent space for IL-23 blockers |
| Strategic Considerations |
Patent strong in sequence claims, but susceptibility to prior art challenges on therapeutic methods |
Key Takeaways
- U.S. Patent 9,662,398 secures a significant position in IL-23 antibody therapeutics through specific sequence claims and broad method coverage.
- The patent landscape is highly competitive, with major players patenting similar or overlapping molecules, emphasizing the importance of careful freedom-to-operate analyses.
- Biological sequence claims provide strong protection but face potential patentability challenges if prior art emerges.
- The patent's breadth supports licensing opportunities, especially in the expanding autoimmune biologics market.
- Strategic patent filing with extensive family coverage enhances global protection, making it a critical asset for Amgen’s IL-23 portfolio.
FAQs
Q1: How does U.S. Patent 9,662,398 compare to other IL-23 antibodies?
It provides sequence claims specific to certain monoclonal antibodies against IL-23 p19, offering narrower but more enforceable protection relative to broader antibody patents that may encompass entire classes.
Q2: Can competitor companies develop similar IL-23 antibodies without infringing?
Potentially, if they design structurally distinct antibodies that do not fall within the scope of the specific sequences or methods claimed, though patent landscape analysis is essential.
Q3: What is the significance of antibody sequence claims?
They legally protect specific molecular structures, preventing others from making, using, or selling antibodies with identical or highly similar amino acid sequences.
Q4: Are method-of-use claims valuable in this patent?
Yes, they extend protection to therapeutic methods, which are critical in biologic drug commercialization, although they are often narrower legally than composition claims.
Q5: How does patent expiry impact IL-23 biologics?
Typically, patents filed around 2014 expire around 2034-2035, after which biosimilar or generic versions might enter the market, affecting market exclusivity and pricing.
References
- U.S. Patent No. 9,662,398.
- Amgen Inc. official patent filings and published patent family data, 2017–2023.
- Market research reports: Allied Market Research, 2022.
- Patent landscape reports: IAM Market Intelligence, 2022.
More… ↓
⤷ Start Trial
|
